Zhi Tong Cai Jing·2025-12-09 13:46Core Viewpoint - Fosun Pharma has signed a licensing agreement with Pfizer for the development and commercialization of the oral small molecule GLP-1 receptor agonist YP05002, which is aimed at treating type 2 diabetes and obesity-related diseases [1][2]. Group 1 - The licensing agreement grants Pfizer exclusive rights to develop, use, produce, and commercialize YP05002 globally across all therapeutic areas for humans and animals [1]. - Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of $150 million and up to $350 million in milestone payments based on clinical and commercialization progress [1]. - Additionally, Fosun Pharma could earn up to $1.585 billion in sales milestone payments based on the annual net sales performance of the licensed product [1]. Group 2 - YP05002 is developed in-house by the company and is designed to activate the GLP-1 receptor, promoting insulin secretion and reducing glucagon secretion, while also suppressing gastric emptying and appetite [2]. - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2].